• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.

作者信息

Cappuzzo Federico, Bemis Lynne, Varella-Garcia Marileila

出版信息

N Engl J Med. 2006 Jun 15;354(24):2619-21. doi: 10.1056/NEJMc060020.

DOI:10.1056/NEJMc060020
PMID:16775247
Abstract
摘要

相似文献

1
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.非小细胞肺癌中HER2突变与曲妥珠单抗治疗反应
N Engl J Med. 2006 Jun 15;354(24):2619-21. doi: 10.1056/NEJMc060020.
2
HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients.HER2/neu基因内激酶结构域突变可能是非小细胞肺癌患者对曲妥珠单抗或特定激酶抑制剂反应的主要决定因素。
Lung Cancer. 2005 Aug;49(2):279-80. doi: 10.1016/j.lungcan.2005.02.013. Epub 2005 Apr 9.
3
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.曲妥珠单抗在晚期非小细胞肺癌治疗中的作用：是否有一席之地？聚焦东部肿瘤协作组2598研究
J Clin Oncol. 2004 Apr 1;22(7):1180-7. doi: 10.1200/JCO.2004.04.105. Epub 2004 Feb 23.
4
Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: the importance of patient selection.培美曲塞联合贝伐单抗用于非小细胞肺癌二线治疗：患者选择的重要性。
J Clin Oncol. 2010 Mar 10;28(8):e131; author reply e132. doi: 10.1200/JCO.2009.26.7351. Epub 2010 Jan 25.
5
Improved survival with addition of bevacizumab to paclitaxel and carboplatin in elderly patients with non-small-cell lung cancer.在老年非小细胞肺癌患者中，在紫杉醇和卡铂基础上加用贝伐单抗可提高生存率。
J Clin Oncol. 2008 Apr 20;26(12):2063-4; author reply 2064-5. doi: 10.1200/JCO.2008.16.3337.
6
A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.一例HER2阳性男性乳腺癌伴肺转移患者，对曲妥珠单抗和紫杉醇治疗反应良好。
Breast Cancer. 2009;16(2):136-40. doi: 10.1007/s12282-008-0060-1. Epub 2008 Jun 12.
7
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.曲妥珠单抗、紫杉醇、顺铂与放疗联合用于局部晚期、HER2过表达食管腺癌的I/II期研究
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):405-9. doi: 10.1016/j.ijrobp.2006.08.076. Epub 2006 Nov 9.
8
[A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].1例HER2过表达复发性乳腺癌的临床治疗病例显示对曲妥珠单抗/紫杉醇联合疗法完全缓解
Gan To Kagaku Ryoho. 2006 Sep;33(9):1293-6.
9
HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.新辅助治疗前后非小细胞肺癌中HER2/neu的表达与扩增
Lung Cancer. 2005 Apr;48(1):59-67. doi: 10.1016/j.lungcan.2004.10.010. Epub 2004 Dec 13.
10
ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.ErbB-2抑制可激活Notch-1并使乳腺癌细胞对γ-分泌酶抑制剂敏感。
Oncogene. 2008 Aug 28;27(37):5019-32. doi: 10.1038/onc.2008.149. Epub 2008 May 12.

引用本文的文献

1
Neural interaction explainable AI predicts drug response across cancers.神经交互可解释人工智能预测多种癌症的药物反应。
NAR Cancer. 2025 Sep 3;7(3):zcaf029. doi: 10.1093/narcan/zcaf029. eCollection 2025 Sep.
2
HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities.非小细胞肺癌（NSCLC）中的HER2改变：从生物学、检测到治疗方式的进展
Front Oncol. 2025 Jun 20;15:1624124. doi: 10.3389/fonc.2025.1624124. eCollection 2025.
3
Investigating druggable kinases for targeted therapy in retinoblastoma.
探讨可成药的激酶在视网膜母细胞瘤中的靶向治疗作用。
J Hum Genet. 2024 Sep;69(9):467-474. doi: 10.1038/s10038-024-01267-0. Epub 2024 Jul 1.
4
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories.实体癌的辅助靶向治疗：先驱者与新辉煌
J Pers Med. 2023 Sep 22;13(10):1427. doi: 10.3390/jpm13101427.
5
-Mutant Gastrointestinal Tumors Represent Heterogeneous Molecular Biology, Particularly in Microsatellite Instability, Tumor Mutation Burden, and Co-Mutated Genes: An In Silico Study.- 突变型胃肠道肿瘤呈现出异质性分子生物学特征，尤其是在微卫星不稳定性、肿瘤突变负荷和共突变基因方面：一项计算机模拟研究。
Curr Issues Mol Biol. 2023 Sep 11;45(9):7404-7416. doi: 10.3390/cimb45090468.
6
Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.针对非小细胞肺癌中的表皮生长因子受体家族：复杂性增加与未来展望。
Cancer Biol Med. 2022 Dec 5;19(11):1543-64. doi: 10.20892/j.issn.2095-3941.2022.0540.
7
Deciphering the Impact of Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches.解读改变对非小细胞肺癌的影响：从生物学机制到治疗方法
J Pers Med. 2022 Oct 4;12(10):1651. doi: 10.3390/jpm12101651.
8
Advanced non-small-cell lung cancer: how to manage and exon 20 insertion mutation-positive disease.晚期非小细胞肺癌：如何管理及应对外显子20插入突变阳性疾病。
Drugs Context. 2022 Jul 29;11. doi: 10.7573/dic.2022-3-9. eCollection 2022.
9
HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device.使用基于尺寸的微流控装置从转移性乳腺癌患者中分离出的循环肿瘤细胞中的HER2表达
Cancers (Basel). 2021 Sep 3;13(17):4446. doi: 10.3390/cancers13174446.
10
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.针对非小细胞肺癌（NSCLC）中的 HER2：一线希望？HER2 改变 NSCLC 的治疗策略更新综述。
ESMO Open. 2021 Oct;6(5):100260. doi: 10.1016/j.esmoop.2021.100260. Epub 2021 Aug 31.